A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
Recruiting
Phase 1
Interventional Study
Pneumococcal Infection
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 2 Months – 15 Months
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 210 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria.
This study will look at V118C in toddlers and infants. The goal of the study is to learn how saf…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
Stage 1:
* Is previously vaccinated with 3 routine infant doses of Pneumococcal 20-valent conjugate vaccine (PCV20)
* Is 12 through 15 months of age
Stage 2:
\- Is approximately 2 months of age
Both S…
Contacts